相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Headache service quality: the role of specialized headache centres within structured headache services, and suggested standards and criteria as centres of excellence
T. J. Steiner et al.
JOURNAL OF HEADACHE AND PAIN (2019)
Erenumab: from scientific evidence to clinical practicethe first Italian real-life data
Piero Barbanti et al.
NEUROLOGICAL SCIENCES (2019)
How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice
Cindy Tiseo et al.
JOURNAL OF HEADACHE AND PAIN (2019)
Shaping the future of migraine targeting Calcitonin-Gene-Related-Peptide with the Disease-Modifying Migraine Drugs (DMMDs)
Paolo Martelletti et al.
JOURNAL OF HEADACHE AND PAIN (2019)
Understanding the nature of psychiatric comorbidity in migraine: a systematic review focused on interactions and treatment implications
Thomas Dresler et al.
JOURNAL OF HEADACHE AND PAIN (2019)
Erenumab in chronic migraine with medication overuse Subgroup analysis of a randomized trial
Stewart J. Tepper et al.
NEUROLOGY (2019)
Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine
Messoud Ashina et al.
CEPHALALGIA (2019)
Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions
Messoud Ashina et al.
CEPHALALGIA (2019)
The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal
Raffaele Ornello et al.
JOURNAL OF HEADACHE AND PAIN (2019)
The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice
Kathleen B. Digre
HEADACHE (2019)
European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
Simona Sacco et al.
JOURNAL OF HEADACHE AND PAIN (2019)
Acute withdrawal and botulinum toxin A in chronic migraine with medication overuse: a double-blind randomized controlled trial
Udith A. Pijpers et al.
BRAIN (2019)
ARISE: A Phase 3 randomized trial of erenumab for episodic migraine
David W. Dodick et al.
CEPHALALGIA (2018)
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
Jes Olesen
CEPHALALGIA (2018)
Migraine is first cause of disability in under 50s: will health politicians now take notice?
Timothy J. Steiner et al.
JOURNAL OF HEADACHE AND PAIN (2018)
Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
Spencer L. G. James et al.
LANCET (2018)
Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study
Uwe Reuter et al.
LANCET (2018)
When does chronic migraine strike? A clinical comparison of migraine according to the headache days suffered per month
M. Torres-Ferrus et al.
CEPHALALGIA (2017)
Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
Stewart Tepper et al.
LANCET NEUROLOGY (2017)
A Controlled Trial of Erenumab for Episodic Migraine
Peter J. Goadsby et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The Application of CGRP(r) Monoclonal Antibodies in Migraine Spectrum: Needs and Priorities
Paolo Martelletti
BIODRUGS (2017)
The therapeutic armamentarium in migraine is quite elderly
Paolo Martelletti
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2015)
Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society
S. D. Silberstein et al.
NEUROLOGY (2012)
Adherence with Migraine Prophylaxis in Clinical Practice
Ariel Berger et al.
PAIN PRACTICE (2012)
OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial
S. K. Aurora et al.
CEPHALALGIA (2010)
OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial
H. C. Diener et al.
CEPHALALGIA (2010)
CGRP Receptor Antagonism and Migraine
Lars Edvinsson et al.
NEUROTHERAPEUTICS (2010)
Are Migraineurs at Increased Risk of Adverse Drug Responses?: A Meta-Analytic Comparison of Topiramate-Related Adverse Drug Reactions in Epilepsy and Migraine
J. Luykx et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Allodynia in different forms of migraine
C. Lovati et al.
NEUROLOGICAL SCIENCES (2007)
Migraine prevalence, disease burden, and the need for preventive therapy
R. B. Lipton et al.
NEUROLOGY (2007)
The role of calcitonin gene-related peptide (CGRP) in the generation and maintenance of mechanical allodynia and hyperalgesia in rats after intradermal injection of capsaicin
RQ Sun et al.
PAIN (2003)
分享论文
